 |
News releases
Please be advised that the information posted was accurate at the time of posting, but may be superseded by subsequent news releases.
To automatically receive future news releases, please go to the News
subscription service page.
2010
- 2009
- 2008
- 2007
- 2006
- 2005
- [2004]
- 2003
- 2002
(click to view the full text)
|
December 22, 2004
Æterna Zentaris Grants its Subsidiary Atrium Biotechnologies Marketing Rights for Neovastat |
December 15, 2004
Æterna Zentaris Announces Appointments to its Board, as well as to the Board and Management of its Subsidiary Atrium Biotechnologies |
December 6, 2004
Æterna Zentaris Receives Regulatory Approval for Impavido® in Germany |
November 15, 2004
Clinical Experience on Æterna Zentaris’ Impavido® Published in Clinical Infectious Diseases |
November 4, 2004
Æterna Zentaris Reports Third Quarter 2004
Financial and Operating Results
|
October 28, 2004
Æterna Zentaris Announces Third Quarter Financial Results Conference Call and Webcast |
October 27, 2004
Æterna Zentaris Enters into a License and Collaboration Agreement with Tulane University for a Novel Class of Potential Anti-Cancer Agents – Growth Hormone Releasing Hormone Antagonists |
October 20, 2004
Æterna Zentaris to Present at Two Upcoming Conferences
in the United States and Germany
|
October 7, 2004
Æterna Zentaris Reports Statistically Significant Positive Phase II Data on Cetrorelix in Benign Prostatic Hyperplasia
Broad, seven-study Phase II program on cetrorelix in BPH, endometriosis and uterine myoma now successfully completed. |
October 6, 2004
Æterna Zentaris to Present at Upcoming Investment Conferences in San Francisco and Québec City |
September 30, 2004
Data from Perifosine Phase II Single-Agent Soft Tissue Sarcoma Study Presented at the 16th Annual EORTC-NCI-AACR Conference |
September 27, 2004
Æterna Zentaris to Present New in vitro Data
on Antiangiogenic Properties of Perifosine at
Strategic Research Institute’s Angiogenesis Conference |
September 23, 2004
Æterna Zentaris to Present at Upcoming Scientific and Investment Conferences
|
September 7, 2004
Æterna Zentaris to Present at Orion Healthcare Conference September 13 in Toronto |
August 12, 2004
Æterna Zentaris Enters a
License and Collaboration Agreement with
Spectrum Pharmaceuticals on Fourth Generation
LHRH Antagonist D-63153 after Zentaris Regains Worldwide Rights to D-63153 from Baxter Healthcare
|
August 11, 2004
Æterna Zentaris Reports Second Quarter 2004
Financial and Operating Results
|
August 4, 2004
Æterna Zentaris Announces Second Quarter Financial Results Conference Call and Webcast |
June 7, 2004
Æterna Zentaris Reports Encouraging Results from Phase I Trial of Perifosine in Combination with Radiotherapy at the 2004 American Society of Clinical Oncology (ASCO) Annual Meeting |
June 3, 2004
Æterna Zentaris to Present at Three Upcoming Conferences: ASCO, BIO 2004 and Needham Biotechnology Conference |
May 26, 2004
Æterna Laboratories Holds 2004 Annual Shareholder Meeting and Announces Company Name Change to Æterna Zentaris
|
May 25, 2004
Æterna/Zentaris to Present Today Additional Detailed Positive Phase II Data on Cetrorelix in Gynecological Indications at the 18th World Congress of the International Federation of Fertility Societies (IFFS) |
May 19, 2004
Æterna to Present at UBS Global Specialty Pharmaceuticals Conference May 24 and Annual Shareholder Meeting to be held May 26 |
May 17, 2004
Æterna/Zentaris to Present Detailed Positive Phase II Data on Cetrorelix and New Preclinical Data on Perifosine during Investor and Analyst Day in New York City |
May 17, 2004
Æterna Laboratories added to NASDAQ Biotech Index |
May 4, 2004
Æterna Laboratories Reports First Quarter 2004 Financial and Operating Results |
May 11, 2004
Æterna Laboratories to Hold Investor and Analyst Day on May 17, 2004 in New York City |
April 28, 2004
Æterna Laboratories Announces First Quarter Financial Results Conference Call and Webcast |
April 29, 2004
Æterna/Zentaris and Solvay Report Headline Positive Data from Six Phase II Trials of Cetrorelix in Three indications: Endometriosis, Uterine Myomas and Benign Prostatic Hyperplasia |
March 31, 2004
Æterna subsidiary Zentaris reports positive preclinical results from novel pyrazole compound |
March 29, 2004
Æterna Adopts Shareholder Rights Plan |
March 11, 2004
Æterna expands pipeline as Zentaris subsidiary establishes new research collaborations with university laboratories in France, Germany and Italy |
March 3, 2004
Æterna Subsidiary Atrium Biotechnologies acquires Pure Encapsulations for $50 million in cash |
January 23, 2004
Æterna subsidiary Zentaris and Solvay Pharmaceuticals Sign Extensive Collaboration Agreement |
February 27, 2004
Æterna Laboratories Reports 2003 Fourth Quarter and Full Year Financial Results |
February 20, 2004
Æterna Laboratories Announces Fourth Quarter and 2003 Financial Results Conference Call and Webcast |
February 2, 2004
Æterna through its subsidiary Zentaris signs partnership with Roche in Brazil for new treatment of leishmaniasis, a devastating tropical disease |
April 21, 2004
Æterna subsidiary Zentaris announces initiation of dose ranging study for a novel oral agent that stimulates growth hormone secretion |
April 7, 2004
Æterna subsidiary Zentaris to present final results from Phase I trial of Perifosine in combination with radiotherapy at 2004 American Society of Clinical Oncology (ASCO) Annual Meeting |
April 2, 2004
Æterna subsidiary Zentaris signs new agreement with Ardana Bioscience for LHRH antagonist Teverelix |
 |
 |
